U.S,Ca:18006380796

Contact Us

Get 30% Free Customization on This Report

Published Date: August, 2017

Immunotherapy Drugs Market: Global Industry Analysis, Trends, Market Size & Forecasts up to 2023


Request Discount Enquire Before Buying

The size of the global immunotherapy market was approximately USD 108.5 billion in 2016. The global immunotherapy market is projected to reach USD X.XX billion by 2023, growing with a CAGR between 13.5 % to 14.0% from 2017 to 2023.

Immunotherapy is a biological therapy, which harnesses the ability of the immune system of a human body for combating a disease or an infection. Immunotherapy techniques either involve stimulation of immune system to work smarter against the attack of cancer cells or induction of artificial immune system proteins or some other immune system components to improve the immunity. Immunotherapy is an alternative treatment for multiple type of cancers such as brain, bladder, breast, cervical, colorectal, gastric, kidney, lymphoma, leukemia, lung, ovarian, prostrate and melanoma. In the case of cancer, immunotherapy helps in slowing or stopping the cancer cells growth, stops spreading of cancer to other regions of the body and stimulates the immune system to destroy the cancer cells effectively. Adoptive T-cell transfer, adjuvant immunotherapy, checkpoint inhibitors, cytokines, monoclonal antibodies, therapeutic cancer vaccines and oncolytic virus immunotherapy are some of the types of immunotherapy. Immunotherapy is also termed as living drug, as the t-cells from the patients are re-engineered for creating special antigen receptors. Moreover, immunotherapy is also useful treatment for autoimmune disease, combined immunodeficiency, inflammatory diseases and some other biological infectious diseases.

The global immunotherapy market is driven by Increasing number of patients with lifestyle related illnesses and preference for targeted therapies, which cause minimal side effects. Immunotherapy is gaining importance as an alternative frontline treatment for cancer patients, who are averse to the serious side effects related to the chemotherapy. Increasing number of cancer patients, minimal side effects and increasing awareness among patients are the major factors that are expected to drive the growth of the global immunotherapy drugs market during the forecast period.

The combination of an immunity checkpoint inhibitor with common cold virus has led to a better immune response among some advanced melanoma patients. The undergoing research programmes related to immunotherapy are expected to yield new drugs and effective treatments for multiple sclerosis, mesothelioma, paralysis and other diseases during the forecast period. High cost involved in the manufacturing of immunotherapy drugs is a major challenge for the major players in the market. The high cost of the immunotherapy treatment and high depreciation related to the product cycle are the major restraints for the growth of the global immunotherapy market. Emerging markets are expected to provide opportunities for major players in the global immunotherapy market to expand, due to the increasing demand for alternatives for conventional cancer treatments that are very costly.

Figure. Global Immunotherapy Market by Value 2015 - 2023

Immunotherapy Drugs Market

Segments Covered:

The report segments the global immunotherapy market by product, disease condition and region. On the basis of product, the market is segmented as monoclonal antibodies, checkpoint inhibitors, vaccines, inferon’s and others. Based on disease condition, the market is segmented as cancer, infectious disease, autoimmune disease, and others. Cancer segment has the highest share in the global immunotherapy drugs market as a majority of the drugs available are for various cancer treatments. Increasing demand for monoclonal antibodies, due to its effectiveness in dealing with specific cells or areas with disease is expected to drive the demand for immunotherapy drugs. Moreover, effectiveness of monoclonal antibodies in other therapies is expected to enhance the growth of the global immunotherapy market significantly. The increasing acceptance of low-cost biosimilars of popular biological immunotherapy drugs is also expected to drive the growth of the global immunotherapy drugs market. Furthermore, increasing number of patients with autoimmune diseases is expected to drive demand for immunotherapy drugs during the forecast period.

Geographic Coverage and Analysis:

The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. North-American region is the largest immunotherapy market in the world. Increasing number of patients with autoimmune diseases, infectious diseases and cancer drive the demand for the immunotherapy drugs, as reimbursement plans and insurance make various therapies affordable for them and it drives the growth of the North-American immunotherapy market. The growing number of autoimmune disease and cancer patients drives the growth of the European immunotherapy market. Efficient research & development for developing new drugs and the acceptance of biosimilar immunotherapy drugs are expected to drive the growth of the European immunotherapy drugs market during the forecast period. The presence of large population, increasing number of people with lifestyle related illnesses and the increasing demand for treatments with minimal side effects in countries such as China, India, Indonesia and other countries are expected to propel Asia-Pacific region as the fastest growing immunotherapy drugs market. The research and development related to infectious diseases like HIV is expected to provide positive outlook for African immunotherapy market during the forecast period. Moreover, the need for alternative treatment for cancer, autoimmune, inflammatory and other diseases in developing countries in Africa is expected to provide growth opportunities for the market players. Presence of good healthcare facilities in Middle East is expected to provide opportunities for the growth of demand for immunotherapy drugs, if there is a significant reduction in the prices during the forecast period.

Companies Profiled:

  • F. Hoffmann-La Roche AG,
  • Merck & Co., Inc.,
  • Novartis International AG,
  • Johnson & Johnson,
  • GlaxoSmithKline PLC,
  • Amgen Inc,
  • AstraZeneca PLC,
  • Bristol-Myers Squibb,
  • Galena Biopharma,
  • Inovio Pharmaceuticals.

Report Highlights:

The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand of immunotherapy globally as well as regionally. Moreover, IGR-Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter’s five forces analysis and DRO analysis of immunotherapy. Moreover, the study highlights current market trends and provides forecast from 2017 to 2023. We also have highlighted future trends in the immunotherapy market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. Additionally, the analysis highlights rise and fall in the market shares of the key players in the market. This report will help manufacturers, suppliers and distributors of the immunotherapy market to understand the present and future trends in this market and formulate their strategies accordingly.

The Infinium Advantages

Analyst Support

Get free analyst support for the queries before and post purchasing report.

Customer Satisfaction

Be assured of 100% customer satisfaction about the research and get 24X7 customer support.

400% Growth

Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.

sign up for our newsletter